How AbbVie Operations & Contract Manufacturing Has Prepared Global Parenteral Sites For The Annex 1 Compliance Requirement

By Andrew Hopkins, Director, Microbiological Contamination Control, AbbVie, Jon Best, Director, Business Development, AbbVie

Adapting global sterile manufacturing operations to meet updated regulatory requirements demands a fundamental evolution from traditional monitoring toward a fully integrated Quality Risk Management (QRM) framework. Relying solely on end-point sterility testing or legacy procedural controls is no longer sufficient; sterility assurance must be explicitly engineered into facility design, equipment choices, and daily cleanroom processes. Central to this regulatory paradigm is the implementation of a comprehensive Contamination Control Strategy (CCS), which functions as a living master document evaluating everything from raw material bioburden to environmental controls. Managing these stringent standards requires robust alignment across executive leadership, cross-functional technical teams, and complex supply chain networks.

Discover how aligning operational infrastructure with modern risk-management principles helps drug developers maintain global compliance and safeguard patient safety.